[{"orgOrder":0,"company":"Trigr","sponsor":"Elpiscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"TR009","moa":"Dll4-Notch1","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Trigr \/ Elpiscience Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Elpiscience Biopharmaceuticals"},{"orgOrder":0,"company":"Trigr","sponsor":"Compass Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"CTX-009","moa":"Dll4-Notch1","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Trigr \/ Compass Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Compass Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Trigr

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Compass Therapeutics obtains global rights to TR009, a novel bispecific antibody and inhibitor of the notch pathway targeting DLL4 and VEGF-A.

                          Brand Name : TR009

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 13, 2021

                          Lead Product(s) : CTX-009

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Compass Therapeutics

                          Deal Size : $14.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territor...

                          Brand Name : ABL001

                          Molecule Type : Large molecule

                          Upfront Cash : $7.0 million

                          January 20, 2021

                          Lead Product(s) : Asciminib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Elpiscience

                          Deal Size : $117.0 million

                          Deal Type : Collaboration

                          blank